Portal de Periódicos da CAPES

Tocolysis in the management of preterm prelabor rupture of membranes at 22–33 weeks of gestation: study protocol for a multicenter, double-blind, randomized controlled trial comparing nifedipine with placebo (TOCOPROM)

2021; BioMed Central; Volume: 21; Issue: 1 Linguagem: Inglês

10.1186/s12884-021-04047-2

1471-2393

Elsa Lorthe, Gilles Kayem, Gilles Kayem, Elsa Lorthe, Pierre‐Yves Ancel, Hendy Abdoul, Nelly Briand, Blandine Lehmann, Clémence Cabanne, Stéphane Marret, L. Foix‐L’Hélias, François Goffinet, Thomas Schmitz, Caroline Charlier, Fanny Autret, Élie Azria, Jadot Balitalike, Kareen Billiemaz, Caroline Bohec, Pascal Bolot, Marie Bornes, Hanane Bouchghoul, Malek Bourennane, Florence Bretelle, Lionel Carbillon, C. Castel, Céline Chauleur, R. Corroënne, Karen Coste, Valérie Datin‐Dorrière, Raoul Desbrière, Luc Desfrère, Michel Dreyfus, Marc Dommergues, Xavier Durrmeyer, Géraldine Favrais, Cyril Flamant, Denis Gallot, Julie Gries, Bassam Haddad, Laure Julé, Cécile Laffaille, J. Lepercq, Emmanuelle Letamendia, Fanny De Marcillac, Caroline Miler, Olivier Morel, Karine Norbert, F. Perrotin, C. Poncelet, Laurent Renesme, Claire Roumegoux, Patrick Rozenberg, Mireille Ruiz, Loı̈c Sentilhes, Jeanne Sibiude, D. Subtil, Nadia Tillouche, Héloïse Torchin, Barthélémy Tosello, Éric Verspyck, Alexandre J. Vivanti, Norbert Winer,

Assisted Reproductive Technology and Twin Pregnancy

Abstract Background Preterm prelabor rupture of membranes (PPROM) before 34 weeks of gestation complicates 1% of pregnancies and accounts for one-third of preterm births. International guidelines recommend expectant management, along with antenatal steroids before 34 weeks and antibiotics. Up-to-date evidence about the risks and benefits of administering tocolysis after PPROM, however, is lacking. In theory, reducing uterine contractility could delay delivery and reduce the risks of prematurity and its adverse short- and long-term consequences, but it might also prolong fetal exposure to inflammation, infection, and acute obstetric complications, potentially associated with neonatal death or long-term sequelae. The primary objective of this study is to assess whether short-term (48 h) tocolysis reduces perinatal mortality/morbidity in PPROM at 22 to 33 completed weeks of gestation. Methods A randomized, double-blind, placebo-controlled, superiority trial will be performed in 29 French maternity units. Women with PPROM between 22 0/7 and 33 6/7 weeks of gestation, a singleton pregnancy, and no condition contraindicating expectant management will be randomized to receive a 48-hour oral treatment by either nifedipine or placebo (1:1 ratio). The primary outcome will be the occurrence of perinatal mortality/morbidity, a composite outcome including fetal death, neonatal death, or severe neonatal morbidity before discharge. If we assume an alpha-risk of 0.05 and beta-risk of 0.20 (i.e., a statistical power of 80%), 702 women (351 per arm) are required to show a reduction of the primary endpoint from 35% (placebo group) to 25% (nifedipine group). We plan to increase the required number of subjects by 20%, to replace any patients who leave the study early. The total number of subjects required is thus 850. Data will be analyzed by the intention-to-treat principle. Discussion This trial will inform practices and policies worldwide. Optimized prenatal management to improve the prognosis of infants born preterm could benefit about 50,000 women in the European Union and 40,000 in the United States each year. Trial registration ClinicalTrials.gov identifier: NCT03976063 (registration date June 5, 2019).